The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): a single-arm, open-label, multicenter, phase II study (CheckMate 172).
 
Paolo Antonio Ascierto
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche/Genentech; Ventana Medical Systems
Research Funding - Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Ventana Medical Systems (Inst)
 
Lev V. Demidov
Leadership - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Roche/Genentech
 
Claus Garbe
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche/Genentech
Research Funding - Bristol-Myers Squibb; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche/Genentech
 
Paul Lorigan
No Relationships to Disclose
 
Helen Gogas
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech
 
Christoph Hoeller
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
John B. A. G. Haanen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Pfizer (Inst)
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst)
 
Enrique Espinosa
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Roche/Genentech
 
Tormod Kyrre Guren
No Relationships to Disclose
 
Eva Muñoz-Couselo
No Relationships to Disclose
 
Andree Rorive
Travel, Accommodations, Expenses - Novartis; Roche/Genentech
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Roche/Genentech
Speakers' Bureau - MSD; Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis
 
Reinhard Dummer
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
 
Ana Carneiro
No Relationships to Disclose
 
Geke Hospers
No Relationships to Disclose
 
Frank Hermann
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Joel Jiang
No Relationships to Disclose
 
Dirk Schadendorf
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Grunenthal; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech; Sysmex
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Grunenthal; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech; Sysmex
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech
 
Paul D. Nathan
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche/Genentech
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Research Funding - AstraZeneca (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD